You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 107 No. 6, June 1964 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

5-Hydroxytryptophan Administration in Phenylketonuria

THOMAS L. PERRY, MD; BLUMA TISCHLER, MD

Am J Dis Child. 1964;107(6):586-589.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Introduction

In phenylketonuria an enzymatic defect in the liver results in a failure of conversion of phenylalanine to tyrosine. The alternative metabolic pathways followed by the accumulating phenylalanine have been clarified. However, the exact mechanism by which the metabolic error in turn produces mental deficiency in untreated phenylketonurics has not been established. One possible explanation for the mental deficiency was advanced in 1957 by Paré et al1 who first noted a defect in the 5-hydroxyindole pathway of tryptophan metabolism in phenylketonurics. The presence of serotonin in brain, and the mental abnormalities produced by some serotonin antagonists, have suggested a possible role for this amine in mental function. Paré et al1 suggested that a failure in serotonin production might play some part in the pathogenesis of the mental defect in phenylketonuria.

Since then it has been demonstrated2-4 that rats rendered artificially phenylketonuric by the administration of large amounts . . . [Full Text PDF of this Article]


Author Affiliations

VANCOUVER. BC, CANADA; NEW WESTMINISTER. BC. CANADA

Thomas L. Perry, MD, Department of Pharmacology, The University of British Columbia, Vancouver 8, BC, Canada.; From the Department of Pharmacology, University of British Columbia, Vancouver, Canada and The Woodlands School, New Westminster, Canada.


Footnotes

Received for publication Jan 22, 1964.

Supported by grants from the Medical Research Council of Canada, and the Richard W. Lippman Memorial Fund.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1964 American Medical Association. All Rights Reserved.